Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous increase in cardiovascular mortality. Numerous adipose-tissue-derived factors and beta cell dysfunction contribute to the increased cardiovascular risk in patients with T2DM. Nowadays, numerous pharmacological interventions are available to lower blood glucose levels in patients with type 2 diabetes. Beside more or less comparable glucose lowering efficacy, some of them have shown limited or probably even unfavorable effects on the cardiovascular system and overall mortality. Recently, incretin-based therapies (GLP-1 receptor agonists and DPP-IV inhibitors) have been introduced in the treatment of T2DM. Beside the effects of GLP-1 on insulin secretion, glucagon secretion, and gastrointestinal motility, recent studies suggested a couple of direct cardiovascular effects of GLP-1-based therapies. The goal of this paper is to provide an overview about the current knowledge of direct GLP-1 effects on endothelial and vascular function and potential consequences on the cardiovascular outcome in patients with T2DM treated with GLP-1 receptor agonists or DPP-IV inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Schematic illustration of intracellular insulin signalling (aPKC: atypical Protein-Kinase C, eNOS: endothelial Nitric Oxide Synthase, ET1: Endothelin 1, FOX01: Forkhead Box01, IRS: Insulin Receptor Substrate, MAPK: Mitogen Activated Proteinkinase, MEK: Mitogen Activated Proteinkinase Kinase, NO: Nitric Oxide, PDK: Phosphoinositide-Dependent Kinase, PI3K: Phosphatidylinostol 3 Kinase, RAS, RAF: Proto-Oncogenes, SHC: Adapter Protein; adapted to [6]).](https://figures.cochat.ai/paper-figures/e59842cfba2b418699b2b8139ce25a4e/cardiovascular-benefits-of-glp-1-basedtherapies-in-patients-with-diabetes-figure-2.jpg)
![Figure 3 Postprandial proinsulin/insulin ratio in patients treated with sulfonylurea, insulin Glargine, or DPP-IV inhibitors compared to nondiabetic healthy controls (*: P < 0.05 versus nondiabetic controls adapted to [67]).](https://figures.cochat.ai/paper-figures/0793e9c9c9994ab290ff85428a4e2480/cardiovascular-benefits-of-glp-1-basedtherapies-in-patients-with-diabetes-figure-3.jpg)
![Figure 4 Schematic illustration of GLP-1-receptor-dependent and GLP-1-receptor-independent pathways in the signalling of GLP-1 associated cardiovascular effects (PI3K: phosphatidylinositol 3 kinase; cAMP: cyclic adenosine monophosphate, PKA: protein kinase A, PKB: protein kinase B, GSK3ß: glycogen synthase kinase 3 beta, MEK1/2: components of the MAP kinase cascade, ERK: extracellular-signal-regulated kinase, NO: nitric oxide, eNOS: endothelial nitric oxide synthase, cGMP: cyclic guanosine monophosphate, PKG: protein kinase G; adapted to [69]).](https://figures.cochat.ai/paper-figures/036b615ae95d4bccba96f64637f740ef/cardiovascular-benefits-of-glp-1-basedtherapies-in-patients-with-diabetes-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, GLP-1 analogues also appear to decrease the risk of cardiovascular pathology in patients, according to some studies, and preliminary data suggest they do so to a greater degree than other oral glucose-lowering drugs.262,275–277”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [277]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
RetractedWild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888 · cited 2×
“Following its release from the L-cells into the blood stream, GLP-1 [7– 36] is quickly cleaved by the enzyme dipeptidyl-peptidaseIV (DPP-IV) into the split product GLP-1 [9–39], which results in a half-life time of GLP-1 [7–39] of only 2 minutes.”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“Following its release from the L-cells into the blood stream, GLP-1 [7– 36] is quickly cleaved by the enzyme dipeptidyl-peptidaseIV (DPP-IV) into the split product GLP-1 [9–39], which results in a half-life time of GLP-1 [7–39] of only 2 minutes.”
BackgroundAtherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 2×
“studied the myocardial effects of GLP-1 (739) and GLP-1(9-39) under postischemic conditions in both wild-type and GLP1r (−/−) (GLP-1 receptor knockout mice) [58].”
BackgroundAdipokines: molecular links between obesity and atheroslcerosis
Lau, D. C. W., Dhillon, B., Yan, H., Szmitko, P. E., & Verma, S. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01058.2004 · Cited by 931
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 1×
“In agreement with this findings, treatment with GLP1 or the GLP-1 receptor agonists was found to improve left ventricular function [72, 73] and to reduce circulating levels of brain natriuretic peptide (BNP) [74, 75].”
ResultKlöting, N., Fasshauer, M., Dietrich, A., Kovacs, P., Schön, M. R., Kern, M., Stumvoll, M., & Blüher, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00586.2009 · Cited by 856 · cited 1×
“On the other hand, the release of adiponectin, an anti-inflammatory and vasoprotective adipokine, is reduced in insulin-resistant obese patients and in patients with T2DM [13].”
BackgroundBolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 820
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 1×
“Treatment with GLP1 receptor agonists has been consistently demonstrated to reduce blood pressure, as observed in clinical trials with exenatide or liraglutide [53–57].”
Obesity Accelerates the Progression of Coronary Atherosclerosis in Young Men
McGill, H. C., McMahan, C. A., Herderick, E. E., Zieske, A. W., Malcom, G. T., Tracy, R. E., & Strong, J. P. (2002) · Circulation · doi:10.1161/01.cir.0000018121.67607.ce · Cited by 684
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Diabetes and Endothelial Dysfunction: A Clinical Perspective
Calles-Escandon, J., & Cipolla, M. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0417 · Cited by 657
Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 608
Fundamentals of Endothelial Function for the Clinical Cardiologist
Verma, S., & Anderson, T. J. (2002) · Circulation · doi:10.1161/hc0502.104540 · Cited by 602
Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes
Hu, F. B., Stampfer, M. J., Haffner, S. M., Solomon, C. G., Willett, W. C., & Manson, J. E. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1129 · Cited by 560
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“Treatment with Exenatide significantly inhibited monocyte adhesion in the aorta of C57BL/6 mice [85].”
BackgroundSchramm, T. K., Gislason, G. H., Køber, L., Rasmussen, S., Rasmussen, J. N., Abildstrøm, S. Z., Hansen, M. L., Folke, F., Buch, P., Madsen, M., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.720847 · Cited by 538
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Type 2 Diabetes as a “Coronary Heart Disease Equivalent”
Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2901 · Cited by 452
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Eurich, D. T., McAlister, F. A., Blackburn, D. F., Majumdar, S. R., Tsuyuki, R. T., Varney, J., & Johnson, J. A. (2007) · BMJ · doi:10.1136/bmj.39314.620174.80 · Cited by 362
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Del Prato, S., Barnett, A. H., Huisman, H., Neubacher, D., Woerle, H. ‐., & Dugi, K. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01350.x · Cited by 299
Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas
Weir, G. C., Mojsov, S., Hendrick, G. K., & Habener, J. F. (1989) · Diabetes · doi:10.2337/diab.38.3.338 · Cited by 275
Kirchhoff, K., Machicao, F., Haupt, A., Schäfer, S. A., Tschritter, O., Staiger, H., Stefan, N., Häring, H.-U., & Fritsche, A. (2008) · Diabetologia · doi:10.1007/s00125-008-0926-y · Cited by 265
Festa, A., D’Agostino, R., Mykkänen, L., Tracy, R. P., Zaccaro, D. J., Hales, C. N., & Haffner, S. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.3.562 · Cited by 263
Best, J. H., Hoogwerf, B. J., Herman, W. H., Pelletier, E. M., Smith, D. B., Wenten, M., & Hussein, M. A. (2011) · Diabetes Care · doi:10.2337/dc10-1393 · Cited by 251
Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Reaven, G. M. (2005) · PubMed · Cited by 239
Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226
Should Diabetes Be Considered a Coronary Heart Disease Risk Equivalent?
Whiteley, L., Padmanabhan, S., Hole, D., & Isles, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1588 · Cited by 221
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Rao, A. D., Kuhadiya, N., Reynolds, K., & Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc08-0167 · Cited by 208
Courrèges, J. ‐., Vilsbøll, T., Zdravkovic, M., Le‐Thi, T., Krarup, T., Schmitz, O., Verhoeven, R., Bugáñová, I., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02484.x · Cited by 191
Liu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0468 · Cited by 187
Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
Okerson, T., Yan, P., Stonehouse, A., & Brodows, R. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2009.245 · Cited by 186
TCF7L2 Polymorphisms Modulate Proinsulin Levels and β-Cell Function in a British Europid Population
Loos, R. J. F., Franks, P. W., Francis, R. W., Barroso, I., Gribble, F. M., Savage, D. B., Ong, K. K., O'Rahilly, S., & Wareham, N. J. (2007) · Diabetes · doi:10.2337/db07-0055 · Cited by 169
Insulin Resistance Predicts Mortality in Nondiabetic Individuals in the U.S.
Ausk, K. J., Boyko, E. J., & Ioannou, G. N. (2010) · Diabetes Care · doi:10.2337/dc09-2110 · Cited by 162
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · cited 2×
“In another study, treatment with the GLP-1 receptor agonist Exenatide resulted in a reduction in body weight, waist circumference, total body, and truncal fat mass by 6%, 5%, 11%, and 13%, respectively [52].”
BackgroundResultNordt, T. K., Schneider, D. J., & Sobel, B. E. (1994) · Circulation · doi:10.1161/01.cir.89.1.321 · Cited by 159
Golpon, H. A., Puechner, A., Welte, T., Wichert, P. V., & Feddersen, C. O. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00300-7 · Cited by 158
Diabetes and Endothelial Dysfunction: A Clinical Perspective
Calles-Escandón, J. (2001) · Endocrine Reviews · doi:10.1210/er.22.1.36 · Cited by 155
GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery
Richter, G., Feddersen, O., Wagner, U., Barth, P., Goke, R., & Goke, B. (1993) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1993.265.4.l374 · Cited by 146
Galloway, J. A., Hooper, S. A., Spradlin, C. T., Howey, D. C., Frank, B. H., Bowsher, R. R., & Anderson, J. H. (1992) · Diabetes Care · doi:10.2337/diacare.15.5.666 · Cited by 139
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
Tomas, E., & Habener, J. F. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.007 · Cited by 137
Ceriello, A., Esposito, K., Testa, R., Bonfigli, A. R., Marra, M., & Giugliano, D. (2011) · Diabetes Care · doi:10.2337/dc10-1949 · Cited by 134
Effect of plasminogen activator inhibitor–1 in diabetes mellitus and cardiovascular disease
Lyon, C. J., & Hsueh, W. A. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.014 · Cited by 132
Koska, J., Schwartz, E. A., Mullin, M. P., Schwenke, D. C., & Reaven, P. D. (2010) · Diabetes Care · doi:10.2337/dc09-1961 · Cited by 129
Insulin Action in the Vasculature: Physiology and Pathophysiology
Mather, K., Anderson, T. J., & Verma, S. (2001) · Journal of Vascular Research · doi:10.1159/000051074 · Cited by 127
Zethelius, B., Byberg, L., Hales, C. N., Lithell, H., & Berne, C. (2002) · Circulation · doi:10.1161/01.cir.0000015855.04844.e7 · Cited by 125
Monami, M., Cremasco, F., Lamanna, C., Colombi, C., Desideri, C. M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2011) · Experimental Diabetes Research · doi:10.1155/2011/215764 · Cited by 112
Zethelius, B., Lithell, H., Hales, C. N., & Berne, C. (2005) · Diabetologia · doi:10.1007/s00125-005-1711-9 · Cited by 111
A Prospective Study of Obesity and Risk of Coronary Heart Disease Among Diabetic Women
Cho, E., Manson, J. E., Stampfer, M. J., Solomon, C. G., Colditz, G. A., Speizer, F. E., Willett, W. C., & Hu, F. B. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1142 · Cited by 111
Family History of Diabetes Is a Major Determinant of Endothelial Function
Goldfine, A. B., Beckman, J. A., Betensky, R. A., Devlin, H. M., Hurley, S., Varo, N., Schönbeck, U., Patti, M., & Creager, M. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.02.045 · Cited by 106
Association between serious ischemic cardiac outcomes and medications used to treat diabetes
Margolis, D. J., Hoffstad, O., & Strom, B. L. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1630 · Cited by 104
Cauchi, S., Guerra, S. D., Choquet, H., D’Aleo, V., Groves, C. J., Lupi, R., McCarthy, M. I., Froguel, P., & Marchetti, P. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.01.001 · Cited by 89
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
Davidson, M. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.046 · Cited by 88
Ban, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 88
Cosson, E., Pham, I., Valensi, P. E., Pariès, J., Attali, J. R., & Nitenberg, A. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1422 · Cited by 85
Plasminogen Activator System and Vascular Disease
Nicholl, S. M., Roztocil, E., & Davies, M. G. (2006) · Current Vascular Pharmacology · doi:10.2174/157016106776359880 · Cited by 81
Relationships Among Age, Proinsulin Conversion, and β-Cell Function in Nondiabetic Humans
Fritsche, A., Madaus, A., Stefan, N., Tschritter, O., Maerker, E., Teigeler, A., Häring, H., & Stumvoll, M. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s234 · Cited by 80
Forst, T., Michelson, G., Ratter, F., Weber, M. M., Anders, S., Mitry, M., Wilhelm, B., & Pfützner, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03589.x · Cited by 75
Self-citationLiu, H., Hu, Y., Simpson, R. W., & Dear, A. E. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0387 · Cited by 67
Pratley, R. E., Schweizer, A., Rosenstock, J., Foley, J. E., Banerji, M. A., Pi‐Sunyer, F. X., Mills, D., & Dejager, S. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00835.x · Cited by 65
Glucagon-like peptide-1 (7–36 amide): a potent glucagonostatic and insulinotropic hormone
Matsuyama, T., Komatsu, R., Namba, M., Watanabe, N., Itoh, H., & Tarui, S. (1988) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(88)80063-9 · Cited by 64
Proinsulin Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality
Alssema, M., Dekker, J. M., Nijpels, G., Stehouwer, C. D. A., Bouter, L. M., & Heine, R. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.860 · Cited by 60
Ishizaka, N., Ishizaka, Y., Takahashi, E., Unuma, T., Tooda, E.-I., Nagai, R., Togo, M., Tsukamoto, K., Hashimoto, H., & Yamakado, M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000050142.09911.0b · Cited by 57
Forst, T. M., Hohberg, C., Füllert, S., Lübben, G., Konrad, T., Löbig, M., Weber, M. M., Sachara, C., Gottschall, V., & Pfützner, A. (2005) · Hormone and Metabolic Research · doi:10.1055/s-2005-870322 · Cited by 43
Self-citationDavies, M. J. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000200 · Cited by 41
Wohlin, M. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00283-1 · Cited by 40
Oh, J. Y., Barrett-Connor, E. L., & Wedick, N. M. (2002) · Circulation · doi:10.1161/hc1102.105565 · Cited by 38
Forst, T. M., Hohberg, C., & Pfützner, A. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0028-1119378 · Cited by 32
Self-citationGardiner, S., March, J., Kemp, P., Bennett, T., & Baker, D. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00867.x · Cited by 28
Nordt, T., Bode, C., & Sobel, B. E. (2001) · Diabetologia · doi:10.1007/s001250100618 · Cited by 24
The role of incretins in cardiovascular control
Mafong, D. D., & Henry, R. R. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0005-x · Cited by 24
Stümvoll, M., Fritsche, A., Stefan, N., Hardt, E., & Häring, H. U. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7331 · Cited by 22
Jia, E., Yang, Z., Zhu, T., Wang, L., Chen, B., Cao, K., HUANG, J. C., & Ma, W. (2007) · Cardiology · doi:10.1159/000110488 · Cited by 12
Pscherer, S., Larbig, M., von Stritsky, B., Pfützner, A., & Forst, T. M. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600318 · Cited by 11
Self-citationStümvoll, M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.3.1235 · Cited by 8
Research works printed but not linked: 4
- 2005, Panminerva Medica, 47, 201
- 10.1185/030079907X253870 · doi:10.1185/030079907x253870 · Paper page
- 1993, American Journal of Physiology, 265, L374
- 2009, European Heart Journal, 30, 917
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Endothelial Dysfunction in Diabetes: Pathogenesis, Significance, and Treatment
Hamilton, S. J., & Watts, G. F. (2013) · The Review of Diabetic Studies · doi:10.1900/rds.2013.10.133 · Cited by 149
“GLP-1 may also have a direct modulatory effect on several cardiovascular pathways involved in atherogenesis [186].”
BackgroundSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Song, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep10202 · Cited by 76
Mahmoud, A. M., Wilkinson, F. L., Jones, A. M., Wilkinson, J. A., Romero, M., Duarte, J., & Alexander, M. Y. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.08.013 · Cited by 74
“to an atherogenic milieu, contributing to endothelial dysfunction [6].”
Metadata
- Authors
- Forst, T., Weber, M. M., & Pfützner, A.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Institute for Clinical Research and Development, 55116 Mainz, Germany
- Corresponding author
- Forst, Thomas
- Venue
- Experimental Diabetes Research
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-9
- ISSN
- 1687-5214 (ISSN-L)
- 1687-5303
- PMC
- PMC3345223
- OpenAlex
- W2102467882
- Cited by
- 44
- References
- 91
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 2 · 2013: 6 · 2012: 2
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Experimental Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- type 2 diabetes, GLP-1 receptor agonists, DPP-4 inhibitors, incretin-based therapy, endothelial dysfunction, vascular dysfunction, cardiovascular risk, cardiovascular mortality, beta-cell dysfunction
- MeSH terms
- Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Endothelium, Vascular, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.